Numinus recently completed an over-subscribed private placement and is expected to announce an over-subscribed sub receipt financing shortly, positioning the company well for execution and growth opportunities.
Backstopped by stable cannabis revenue
Sustainable cannabis revenue driven by our testing and processing laboratory provides us a foundation for growth – differentiating us from others in the psychedelics space.
Numinus’ fully built and paid for facility has the capacity to take on THC and CBD product, and is set to be a progressive player in the hemp-derived CBD and cannabis extraction markets upon issuing of its standard processing licence by Health Canada, expected in Q1 2020.
Numinus is a fully integrated operating company at the forefront of the transformative change in treating the growing prevalence of mental health issues and desire for greater wellness.
They will be one of the first publicly traded companies licensed to test, sell and deliver psychedelic therapies
Their unique growth platform includes a testing and processing facility that can leverage the emerging market of psychedelic therapies to treat mental illness, addictions and PTSD, as well as an established and fully integrated treatment and healing centre model that they plan to scale nationally.
Sustainable cannabis revenue through their laboratory and processing facility will help fund growth plans.
Source: Numinus, Psychedelic Finance Feature